IP Library Granted Patent US 12,590,172
Granted Patent B2
US 12,590,172 · App. 18/192,861 · Granted Mar 31, 2026

Complex-specific antibodies and antibody fragments and its use

Inventors: Stefan Haertle (Mammendorf, DE); Christian Frisch (Munich, DE); Achim Knappik (Moorenweis, DE)
Assignee: MORPHOSYS GMBH
C07K16/4241C07K16/241C07K16/243C07K16/42G01N33/686C07K2317/30C07K2317/32C07K2317/55G01N2470/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,590,172
App. No.
18/192,861
Granted
Mar 31, 2026
Kind
B2
Abstract

The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.

Claims (13)

1 . A method of detecting, quantifying or monitoring a level of a complex of a specific cognate antibody or fragment thereof and its antigen, in a sample, the method comprising the steps of:

(a) screening a library of antibodies or antibody fragments against the complex of the specific cognate antibody and its antigen in the presence of the unbound antigen and an antibody different from the specific cognate antibody that has the same isotype as the specific cognate antibody,

(b) isolating a complex of the specific cognate antibody and its antigen and the bound antibodies or antibody fragments,

(c) identifying and isolating an isolated monoclonal antibody, or functional fragment thereof which specifically binds to a complex of a specific cognate antibody and its antigen and does not bind either said cognate antibody or said antigen alone;

(d) contacting said sample with the identified, isolated monoclonal antibody or fragment thereof,

(e) detecting said isolated monoclonal antibody or fragment bound to said complex, and

(f) correlating said isolated monoclonal antibody or fragment thereof bound to said complex with the concentration of the antigen-bound cognate antibody,

wherein said sample is obtained from an experimental animal or a human and said complex is detected using EIA, ELISA, RIA, indirect competitive immunoassay, direct competitive immunoassay, non-competitive immunoassay, sandwich immunoassay, agglutination assay or mesoscale discover (MSD).

2 . The method of claim 1 wherein said isolated monoclonal antibody or fragment thereof binds to at least parts of the CDR regions of the cognate antibody.

3 . The method of claim 1 wherein said isolated monoclonal antibody or fragment thereof is a human or humanized antibody or fragment thereof.

4 . The method of claim 1 wherein said cognate antibody or fragment thereof is a therapeutic antibody or a therapeutic antibody fragment.

5 . The method of claim 1 wherein said cognate antibody or fragment thereof is a diagnostic antibody or a diagnostic antibody fragment.

6 . The method of claim 1 wherein the antigen is a cytokine or a receptor.

Assignments (2)
CHANGE OF NAME Recorded May 1, 2025
From: MORPHOSYS AG
To: MORPHOSYS GMBH
Reel/Frame 071149/0626 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2023
From: HAERTLE, STEFAN; FRISCH, CHRISTIAN; KNAPPIK, ACHIM
To: MORPHOSYS AG.
Reel/Frame 063190/0670 →
Continuity (5)
Continuation 16925824 · Jul 10, 2020
Continuation 15846686 · Dec 19, 2017
Division 14418089
Provisional Application 61684836 · Aug 20, 2012
Related Publication 20240067753A1 · Feb 29, 2024
References Cited (44)
US 5932704A · Jubinsky · 1999 [cited by applicant]
US 7867495B2 · Steidl et al. · 2011 [cited by applicant]
US 10774154B2 · Haertle et al. · 2020 [cited by applicant]
US 20090068172A1 · Kaymakcalan et al. · 2009 [cited by applicant]
US 20100040605A1 · Azuma et al. · 2010 [cited by applicant]
US 20100167307A1 · Buechler et al. · 2010 [cited by applicant]
US 20110195438A1 · Kondou et al. · 2011 [cited by applicant]
US 20110236994A1 · Albltar · 2011 [cited by applicant]
US 20120157663A1 · Azuma · 2012 [cited by applicant]
EP 2289943 · 2005 [cited by applicant]
JP 58177921 · 1983 [cited by applicant]
JP 2000055917 · 2000 [cited by applicant]
JP 2005533236 · 2005 [cited by applicant]
WO 2003024993 · 2003 [cited by applicant]
WO 2006066912 · 2006 [cited by applicant]
WO 2009032128 · 2009 [cited by applicant]
WO 2009142221 · 2009 [cited by applicant]
WO 2011010673 · 2011 [cited by applicant]
EP12180835.6 extended European Search Report dated Nov. 30, 2012. [cited by applicant]
AbD Serotech, “Human anti Adalimumab (drug/target complex) HCA206 Fab”, 1. Sep. 2012. [cited by applicant]
AbD Serotech, “Human anti Adalimumab (drug/target complex) HCA207 IgG”, 1. Sep. 2012. [cited by applicant]
PCT/EP2013/066625 International Search Report dated Dec. 5, 2013. [cited by applicant]
Tornetta, et al.: “Isolation of human anti-idiotypic antibodies by phage display for clinical Immune response assays”, Journal of Immunological Methods 328 (2007) 34-44, Sep. 4, 2007. [cited by applicant]
Charles, et al.: “Regulation of Cytokines, Cytokine Inhibitors, and Acute-Phase Proteins Following Anti-TNF—a Therapy in Rheumatoid Arthritis”, J Immunol 1999;163;1521-1528. [cited by applicant]
Poster AbD Serotech, Härtle, et al.: “Fast Development of Highly Specific Fully Human Anti″ Idiotypic Antibodies”, Poster for Ab Engineering, Ab Therapetics, Dec. 6, 2009. [cited by applicant]
AbD Serotech, brochure 2012, “Anti-Idiotypic Antibodies Supporting the Development of Human Antibody Therapeutics & Preclinical Research”. [cited by applicant]
Kuang B. 2010 Bioanalysis, 2(6):1125-40. [cited by applicant]
Machine Translation of JP2000055917A 10 pages Feb. 25, 2000. [cited by applicant]
Morphosys, MorphoSys Strengthens Patent Position on Lead Program MOR103, retrieved from https://www.morphosys.com/media-investors/media-center/morphosys-strengthens-patent-position-on-lead-program-mor103, 3 pages May 15… [cited by applicant]
Office Communication dated Sep. 2, 2015 in U.S. Appl. No. 14/418,089, filed Jan. 29, 2015 [cited by applicant]
Office Communication dated Feb. 23, 2016 in U.S. Appl. No. 14/418,089, filed Jan. 29, 2015. [cited by applicant]
Office Communication dated Aug. 1, 2016 in U.S. Appl. No. 14/418,089, filed Jan. 29, 2015. [cited by applicant]
Office Communication dated Sep. 26, 2016 in U.S. Appl. No. 14/418,089, filed Jan. 29, 2015. [cited by applicant]
Office Communication dated Feb. 13, 2017 in U.S. Appl. No. 14/418,089, filed Jan. 29, 2015. [cited by applicant]
Office Communication dated May 23, 2017 in U.S. Appl. No. 14/418,089, filed Jan. 29, 2015. [cited by applicant]
Office Communication dated August Sep. 20, 2017 in U.S. Appl. No. 14/418,089, filed Jan. 29, 2015. [cited by applicant]
Office Communication dated Dec. 12, 2017 in U.S. Appl. No. 14/418,089, filed Jan. 29, 2015. [cited by applicant]
Extended European Search Report dated Jun. 3, 2019 in corresponding application EP 19168061.0. [cited by applicant]
Office Communication dated Jul. 23, 2019 in U.S. Appl. No. 15/846,686, filed Dec. 19, 2017. [cited by applicant]
Office Communication dated Dec. 4, 2019 in U.S. Appl. No. 15/846,686, filed Dec. 19, 2017. [cited by applicant]
Office Communication dated Mar. 19, 2020 in U.S. Appl. No. 15/846,686, filed Dec. 19, 2017. [cited by applicant]
Office Communication dated May 19, 2020 in U.S. Appl. No. 15/846,686, filed Dec. 19, 2017. [cited by applicant]
Office Communication dated Jul. 22, 2022 in U.S. Appl. No. 16/925,824, filed Jul. 10, 2020. [cited by applicant]
Office Communication dated Sep. 30, 2022 in U.S. Appl. No. 16/925,824, filed Jul. 10, 2020. [cited by applicant]